Navigation Links
Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution
Date:9/29/2010

Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution -- ABBOTT PARK, Ill., Sept. 29 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, FDA Approval Click to view news release full screen  

Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution

   

RevitaLens Ocutec Multi-purpose Disinfecting Solution provides high-quality disinfection of silicone hydrogel and conventional soft contact lenses

ABBOTT PARK, Ill., Sept. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) market clearance for RevitaLens Ocutec™, a unique next-generation multi-purpose disinfecting solution for silicone hydrogel and conventional soft contact lenses.  

RevitaLens Ocutec Multi-purpose Disinfecting Solution delivers high-quality disinfection and comfort for the user, with the convenience of a single bottle. The solution was developed in cooperation with world class silicone hydrogel, microbiology and chemistry experts and with input from more than 600 eyecare professionals.

"This advanced, next-generation solution establishes a new standard of disinfecting technology for contact lens wearers," said Jim Mazzo, senior vice president, Abbott Medical Optics. "Proper contact lens care, including a rub and rinse regimen using RevitaLens Ocutec, will help patients achieve clean and comfortable lenses while enhancing overall lens-wearing satisfaction."

It is estimated that there are 125 million contact lens wearers worldwide. Multi-purpose solutions (MPS) represent the majority of systems used for the care of soft contact lenses. These comprise a single solution for the rinsing, cleaning, disinfection and storage of lenses and are typically composed of a preservative, buffer system and other agents to aid in lens cleaning and comfort.

Key characteristics of RevitaLens Ocutec Multi-purpose Disinfecting Solution include:

  • high microorganism kill rates;
  • removes proteins from the lens surface;
  • effectively kills Acanthamoeba and Fusarium;
  • reduces corneal staining;
  • minimizes risk of eye complications.

  • "It is gratifying to see the contact lens solution industry developing new products, such as RevitaLens Ocutec, that enhance patient safety by providing the delicate balance of superior disinfection, comfort and convenience," said Dr. Thomas Quinn, an optometrist in Athens, Ohio.

    Abbott plans to begin retail shipment of RevitaLens Ocutec Multi-purpose Disinfecting Solution in the U.S. this October. The product also has CE Mark approval in Europe.

    About AbbottAbbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

    Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


    '/>"/>

    SOURCE Abbott
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Abbotts XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
    2. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
    3. Abbotts Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
    4. The Deal Names Abbott Top Dealmaker for Third Consecutive Year
    5. Abbott Declares 347th Consecutive Quarterly Dividend
    6. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
    7. Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine
    8. Abbott Honored for Workplace Leadership for the Tenth Consecutive Year by Working Mother Magazine
    9. Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance
    10. Abbott Completes Acquisition of Piramals Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India
    11. Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/5/2016)... 2016 Research ... the  "Europe Thrombocytopenia Market and Competitive ... their offering.       (Logo: ... latest research Europe Thrombocytopenia Market and ... comprehensive insights into Thrombocytopenia pipeline products, ...
    (Date:5/4/2016)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... First Quarter 2016 Highlights , Generated Cash ... Flow") of $13.6 million for the first quarter of ... for the first quarter of 2016; , Paid ...
    (Date:5/4/2016)... Israel , May 4, 2016 ... BiondVax,s CEO, Dr. Ron Babecoff , will be attending ... York City . On Thursday, May 5, ... a conference presented by Joseph Gunner & Co, ... The BiondVax presentation that Dr. Babecoff will be using is ...
    Breaking Medicine Technology:
    (Date:5/6/2016)... ... 06, 2016 , ... In honor of Military Spouse Appreciation ... and the National Military Family Association, a nonprofit that works to strengthen and ... scholarship recipient of 2016. , “Being awarded this scholarship by Career Step, ...
    (Date:5/6/2016)... ... May 06, 2016 , ... ... at CareFirst Blue Cross BlueShield and Former Principal Deputy Administrator at Centers for ... an Anthem Company; Steve Ondra, MD, Chief Medical Officer at Health Care Service ...
    (Date:5/5/2016)... ... May 05, 2016 , ... ... injectables (LAIs), today announced a development collaboration with the Australian critical medicine ... mental disorders such as schizophrenia. , LAI medicines can offer improved therapeutic benefits ...
    (Date:5/5/2016)... , ... May 05, 2016 , ... ... to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term warfarin ... first offering the procedure in April of 2015, Florida Hospital Pepin Heart Institute ...
    (Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... some macroalgae can use ultraviolet light A (UV-A) for photosynthesis, researchers Juntian Xu ... red, green, and brown seaweeds. The pair observed that when photosynthetically active radiation ...
    Breaking Medicine News(10 mins):